The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Real-world bortezomib prescribing patterns and outcomes in NDMM
Fieke Hoff, MD, PhD, UT Southwestern Medical Center, Dallas, TX, discusses a retrospective observational study evaluating bortezomib prescribing patterns in the US using a large nationwide database. The study concluded that once-weekly bortezomib should be considered the standard of care (SOC) for patients with newly diagnosed multiple myeloma (NDMM). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
